🔬 Respiratory Assessment
History Taking — Key Domains
Dyspnoea Scales
| MRC / mMRC Grade | Description |
|---|---|
| 0 | Breathless only on strenuous exercise |
| 1 | Short of breath when hurrying on level or up slight hill |
| 2 | Walks slower than peers on level; stops after ~1 mile |
| 3 | Stops for breath after ~100m on level |
| 4 | Too breathless to leave house; breathless dressing |
Cough & Sputum Assessment
- Productive — purulent (yellow/green: infection), mucoid (white/clear: COPD/asthma), pink frothy (pulmonary oedema)
- Dry / non-productive — post-viral, ACE inhibitor-induced, interstitial lung disease
- Haemoptysis — blood-stained sputum; always investigate (TB, malignancy, PE, bronchiectasis)
- Volume — >30ml/day suggests bronchiectasis
- Wheeze — expiratory (asthma/COPD) vs inspiratory stridor (upper airway obstruction)
- Pleuritic chest pain — sharp, worsened by breathing/coughing (PE, pneumonia, pleurisy)
Physical Examination
Inspection
- Respiratory rate — normal 12–20 breaths/min; tachypnoea ≥20
- Accessory muscles — SCM, scalenes, intercostals in use → increased work of breathing
- Cyanosis — central (lips/tongue) vs peripheral (fingertips)
- Clubbing — lung cancer, bronchiectasis, cystic fibrosis, interstitial lung disease
- Barrel chest — AP diameter ≥ transverse; COPD/emphysema, hyperinflation
- Pursed-lip breathing — COPD auto-PEEP mechanism
Palpation & Percussion
- Trachea position — central (normal); deviated away from effusion, towards collapse/fibrosis
- Chest expansion — reduced bilaterally (COPD); unilateral reduction (pneumonia, effusion)
- Resonant — normal lung
- Dull — consolidation (pneumonia), pleural effusion
- Hyper-resonant — pneumothorax, emphysema
- Crackles (fine) — pulmonary fibrosis, early pulmonary oedema
- Crackles (coarse) — pneumonia, bronchiectasis, secretions
- Wheeze (polyphonic) — asthma, COPD (generalised)
- Wheeze (monophonic) — fixed obstruction, foreign body
- Pleural rub — leathery, creaking; pleurisy, pleural thickening
- Bronchial breathing — harsh, equal I:E; consolidation
Oxygen Assessment & ABG Interpretation
SpO₂ & Oxygen Targets
- Normal SpO₂: 94–98%
- COPD/CO₂ retainer target: 88–92%
- Acutely ill (non-COPD): 94–98%
- Pulse oximetry limitations: poor perfusion, nail polish, pigmentation, motion artefact, carbon monoxide
- NEWS2 SpO₂ scale 1 (normal): 95–96 = 1pt, 93–94 = 2pt, ≤92 = 3pt
- NEWS2 SpO₂ scale 2 (COPD): 93–94 = 0pt, 95–96 = 1pt, ≥97 = 3pt
ABG Interpretation (Stepwise)
| Parameter | Normal Range |
|---|---|
| pH | 7.35 – 7.45 |
| PaO₂ | 10.6 – 13.3 kPa (80–100 mmHg) |
| PaCO₂ | 4.7 – 6.0 kPa (35–45 mmHg) |
| HCO₃⁻ | 22 – 26 mmol/L |
| Base excess | −2 to +2 mmol/L |
4-Step ABG method: 1. Acidosis/alkalosis (pH) → 2. Respiratory cause? (CO₂) → 3. Metabolic cause? (HCO₃) → 4. Compensation? → 5. Oxygenation (PaO₂)
Peak Flow Monitoring
- Use Wright or mini-Wright peak flow meter; standing position preferred
- Technique: maximal inspiratory effort → seal lips on mouthpiece → blast out as hard and fast as possible
- Record best of 3 attempts; compare to predicted (based on age/height/sex) or personal best
- Personal best = highest value achieved over 2–3 weeks when well
🟢 Green Zone ≥80%
Well-controlled. Continue usual medications. No action needed.
🟡 Amber Zone 50–79%
Caution. Increase reliever use. Review if worsening. May add oral prednisolone.
🔴 Red Zone <50%
Medical emergency. Immediate nebulised salbutamol, O₂, IV access, call doctor now.
Chest X-Ray: Basic Nurse Interpretation
| Finding | Appearance | Key Features |
|---|---|---|
| Pneumonia | Opacity / consolidation | Air bronchograms; lobar or patchy; unilateral or bilateral |
| Pleural Effusion | Homogenous opacity, lower zone | Blunting of costophrenic angle; meniscus sign; tracheal deviation (large) |
| Pneumothorax | Absent lung markings at periphery | Visible pleural line; no lung markings beyond it; tracheal deviation (tension) |
| COPD | Hyperinflation | Flat diaphragms; >6 ribs visible anteriorly; large lung volumes |
| Normal | Clear lung fields | Costophrenic angles sharp; heart <50% thoracic width; clavicles symmetric |
Nurse note: Always check the RSVP systematic approach — Rotation, Superimposition, Ventilation/Volume, Pathology. Flag abnormalities to the medical team and document your findings.
NEWS2 Respiratory Rate Scoring
| Respiratory Rate (breaths/min) | NEWS2 Score |
|---|---|
| ≤8 | 3 |
| 9–11 | 1 |
| 12–20 | 0 |
| 21–24 | 2 |
| ≥25 | 3 |
🫁 Respiratory Conditions
COPD — Chronic Obstructive Pulmonary Disease
GOLD Staging (post-bronchodilator FEV₁)
| GOLD Stage | FEV₁ % Predicted | Severity |
|---|---|---|
| GOLD 1 | ≥80% | Mild |
| GOLD 2 | 50–79% | Moderate |
| GOLD 3 | 30–49% | Severe |
| GOLD 4 | <30% | Very Severe |
Triple Therapy Inhalers
- LAMA (Long-acting muscarinic antagonist) — e.g. tiotropium, umeclidinium; reduces bronchospasm
- LABA (Long-acting beta-2 agonist) — e.g. salmeterol, formoterol, vilanterol; bronchodilation
- ICS (Inhaled corticosteroid) — e.g. fluticasone, budesonide; reduces exacerbations in frequent exacerbators
- Combined devices: Trelegy Ellipta (FF/UMEC/VI), Trimbow (BDP/FF/GB), Breztri Aerosphere
Controlled Oxygen
Target SpO₂ 88–92% in known/suspected COPD. Use Venturi 24–28%. Avoid over-oxygenation — hypoxic drive risk. Titrate by 1% increments guided by ABG.
Bronchodilators
Nebulised salbutamol 2.5–5mg + ipratropium 500mcg q4–6h. Driven by air not oxygen in COPD. SABA + SAMA combination superior to either alone.
NIV — BiPAP
Indicated for acute hypercapnic respiratory failure (pH <7.35, PaCO₂ >6.5kPa). Initial settings: IPAP 12–20, EPAP 4–6 cmH₂O. Aim pH >7.35 at 1 hour.
COPD vs CPAP vs BiPAP: CPAP delivers one constant pressure (for CPO/obstructive sleep apnoea). BiPAP delivers two pressures (IPAP + EPAP) — preferred for COPD exacerbation with hypercapnia as it provides inspiratory support.
Asthma — BTS/GINA Stepwise Management
| BTS Step | Treatment |
|---|---|
| Step 1 | SABA (salbutamol) PRN only |
| Step 2 | Add low-dose ICS (beclometasone 200–400mcg/day) |
| Step 3 | Add LABA (salmeterol) or increase ICS to medium dose |
| Step 4 | Increase ICS to high dose; add LTRA (montelukast) or LAMA |
| Step 5 | Add oral prednisolone; refer to specialist; consider biologics (omalizumab, mepolizumab) |
Acute Severe Asthma (PEFR 33–50% best): SpO₂ <92%, RR ≥25, HR ≥110, unable to complete sentences. Nebulised salbutamol 5mg + ipratropium 0.5mg (back-to-back × 3), O₂ to maintain ≥94%, oral/IV prednisolone 40–50mg.
Life-Threatening Asthma (PEFR <33% best): Silent chest, cyanosis, bradycardia, altered consciousness. Add IV magnesium sulphate 1.2–2g over 20 min. Prepare for ICU/intubation. Consider IV aminophylline (specialist only).
🧮 CURB-65 Pneumonia Severity Score — Interactive Calculator
Score 1 point for each feature present. Guides setting of care for community-acquired pneumonia (CAP).
Pleural Effusion
Light's Criteria (Exudate vs Transudate)
Exudate if ANY of: Fluid protein/serum protein >0.5 | Fluid LDH/serum LDH >0.6 | Fluid LDH >2/3 upper normal serum LDH
- Transudate causes: heart failure, cirrhosis, nephrotic syndrome, hypoalbuminaemia
- Exudate causes: pneumonia (parapneumonic), malignancy, TB, PE, pancreatitis
Nursing Role in Aspiration
- Explain procedure; obtain informed consent
- Position: sitting upright leaning forward over bedtable or lateral decubitus
- Ultrasound guidance — standard of care, reduces complications
- Diagnostic aspiration: 20–50mL sent for protein, LDH, glucose, cytology, MC&S, pH
- Therapeutic aspiration: drain up to 1.5L at one time (more → re-expansion pulmonary oedema)
- Post-procedure: CXR; monitor SpO₂, HR, BP, pain
Pulmonary Embolism
Wells Score (Simplified)
- Clinical signs of DVT — 3 points
- Alternative diagnosis less likely than PE — 3 points
- HR >100 — 1.5 points
- Immobilisation or surgery in last 4 weeks — 1.5 points
- Previous DVT/PE — 1.5 points
- Haemoptysis — 1 point
- Active malignancy — 1 point
- >4 = High probability; ≤4 = Low/intermediate
Management
- D-dimer: High sensitivity, low specificity. Use only in low/intermediate probability. Positive → CT-PA.
- CT-PA: Definitive diagnosis. Nursing: IV access, creatinine check, contrast allergy assessment
- Anticoagulation: LMWH (enoxaparin) → DOAC (rivaroxaban, apixaban) or warfarin. Duration 3–6 months minimum
- Thrombolysis: Massive PE (haemodynamic instability). Alteplase 100mg over 2h. Monitor for bleeding
Pneumothorax
| Type | Definition | Management |
|---|---|---|
| Primary Spontaneous | No underlying lung disease; young, tall males; smoking risk factor | Small (<2cm rim on CXR) + stable: observation, discharge with 2-week follow-up. Large or symptomatic: aspiration or intercostal drain |
| Secondary Spontaneous | Underlying lung disease (COPD, asthma, fibrosis, cancer) | More serious. All require admission. Aspiration if <2cm + age <50. Drain for larger or failed aspiration. |
| Tension Pneumothorax | Air trapped under pressure; tracheal deviation, haemodynamic instability | EMERGENCY — immediate needle decompression (2nd ICS, MCL), then chest drain |
💨 Inhaler Techniques
MDI — Pressurised Metered Dose Inhaler
- Remove cap; shake inhaler vigorously for 5 seconds
- Hold inhaler upright; breathe out gently and fully (but not forcefully)
- Seal lips around mouthpiece (or hold 2–4cm from open mouth for open-mouth technique)
- Begin to inhale slowly and deeply — press canister down once at start of inhalation
- Continue inhaling slowly for 3–5 seconds until lungs are full
- Remove inhaler; hold breath for 10 seconds (or as long as comfortable)
- Breathe out slowly through the nose or pursed lips
- Wait 30–60 seconds before second puff
- Replace cap; rinse mouth with water after ICS
Spacer device: Use with all MDIs when possible — improves drug delivery by 30–50%, reduces oropharyngeal deposition and ICS side-effects. Essential for children, elderly, those with poor coordination. Clean spacer weekly with warm soapy water; allow to air-dry.
DPI — Dry Powder Inhalers (Turbuhaler, Accuhaler, Ellipta)
Turbuhaler (Bricanyl, Pulmicort)
- Unscrew and remove cap
- Hold upright; twist base fully right then left (click)
- Exhale away from device
- Seal lips; inhale FAST and DEEPLY
- Hold breath 10 seconds
- Repeat if needed; replace cap
Accuhaler (Seretide, Flixotide)
- Hold flat; open mouthpiece cover
- Slide lever until it clicks (loads dose)
- Exhale away from device
- Seal lips; inhale fast and deeply
- Hold breath 10 seconds
- Close mouthpiece; rinse mouth after ICS
Ellipta (Trelegy, Incruse, Relvar)
- Slide cover down until click
- Exhale away from device
- Seal lips; inhale fast and deeply
- Hold breath 3–4 seconds
- Slide cover up to close
- Rinse mouth after ICS-containing device
Key DPI difference vs MDI: DPIs require a FAST, DEEP inhalation (peak inspiratory flow ≥60L/min to disperse powder). Do NOT shake DPIs. Do NOT use spacer with DPIs. Inadequate inspiratory effort = insufficient drug delivery.
SMI — Soft Mist Inhaler (Respimat — Spiriva Respimat, Stiolto)
- Hold inhaler upright; remove cap; push safety catch
- Turn base in direction of arrows until it clicks (load dose)
- Flip cap open
- Exhale gently and fully, away from inhaler
- Seal lips; begin slow, deep inhalation — press dose release button simultaneously
- Continue inhaling slowly for ~5 seconds until lungs full
- Hold breath 10 seconds; breathe out gently
SMI key point: Respimat produces a slow, fine mist — requires SLOW inhalation (opposite to DPI). Spacer can be used with Respimat. Suitable for patients unable to coordinate MDI. Duration of mist ~1.5 seconds allows more time to inhale.
Nebuliser — Driving Gas, Setup & Monitoring
Setup & Parameters
- Fill volume: 4–5mL total (add 0.9% NaCl if volume less)
- Flow rate: 6–8 L/min via gas tubing
- Duration: 5–10 minutes until sputter/dry
- Position: nebuliser cup upright; patient sitting if possible
- Mouthpiece preferred over mask (less drug deposited in eyes/face)
- Mask used for children, confused, or fatigued patients
Driving Gas — Critical Distinction
COPD: Drive nebuliser with AIR (piped air or air compressor). Use Venturi oxygen 24–28% separately via nasal cannula if hypoxic. Driving with high-flow O₂ risks hyperoxia and CO₂ retention.
Asthma / non-COPD: Drive nebuliser with OXYGEN at 6–8 L/min. Target SpO₂ ≥94%.
Common Inhaler Errors & Device Selection
Top 7 Inhaler Errors
| Error | Device | Consequence |
|---|---|---|
| Not exhaling before inhalation | All | Reduced lung deposition |
| Inhaling too slowly | DPI | Drug remains in device |
| Inhaling too fast | MDI/SMI | Drug impacts back of throat |
| Not holding breath 10s | All | Drug exhaled before settling |
| Not shaking | MDI | Uneven dose (propellant/drug separation) |
| Not rinsing mouth | ICS inhalers | Oral candidiasis, dysphonia |
| Not loading dose | DPI | No drug delivered |
Device Selection — Patient Factors
- Poor coordination/cognitive impairment: SMI Respimat or MDI + spacer
- Weak inspiratory flow (<30L/min): MDI + spacer; avoid Turbuhaler
- Arthritis / poor manual dexterity: Ellipta or Breezhaler (single-lever); avoid MDI without spacer
- Good coordination + adequate flow: Any DPI or MDI
- Acute severe episode: Nebuliser or MDI + spacer (equivalent efficacy in acute asthma)
- Children <5 years: MDI + spacer + mask
- Nurse demonstrates full technique using placebo device
- Patient demonstrates back to nurse without prompting
- Nurse identifies and corrects specific errors non-judgementally
- Patient demonstrates again; confirm ≥80% correct technique
- Provide written instructions; document education in notes
🩺 Respiratory Procedures
Chest Physiotherapy
Active Cycle of Breathing Technique (ACBT)
- Breathing control — relaxed tidal breathing at patient's own rate, 3–4 breaths
- Thoracic expansion exercises — 3–4 deep breaths with inspiratory hold; may use percussion/vibration
- Forced expiration technique (FET / huff) — 1–2 huffs from mid-lung volume, then breathing control
- Repeat cycle until chest is clear
- Postural drainage — position affected lobe uppermost to drain by gravity (e.g. left lower lobe: right side-lying, foot elevated)
- Upright positioning improves FRC and oxygenation
- Head-of-bed 30–45° for ventilated patients (VAP prevention)
Airway Clearance Devices
| Device | Mechanism | Use |
|---|---|---|
| PEP mask | Positive expiratory pressure | Bronchiectasis, cystic fibrosis, COPD |
| Flutter / Acapella | PEP + oscillation | Loose secretions; COPD, CF, bronchiectasis |
| IPPB | Intermittent positive pressure | Hypoventilation, atelectasis |
| HFCWC vest | High-freq chest wall compression | CF, neuromuscular disease |
Suctioning — Open vs Closed Circuit
Indications
- Inability to clear secretions independently
- Audible/visible secretions in airway
- Decreased SpO₂ with suspected secretions
- Increased airway pressures (ventilated patient)
- Prior to cuff deflation / extubation
- Catheter size: No larger than half the internal diameter of ETT (e.g. 8mm ETT → use Ch12 catheter)
- Suction pressure: 80–120 mmHg adults (60–80 mmHg neonates)
- Duration: <15 seconds per pass; limit to 3 passes
- Pre-oxygenate: 100% FiO₂ for 30–60 seconds before suctioning
Open vs Closed Circuit
| Open | Closed (In-line) | |
|---|---|---|
| Ventilator disconnected | Yes | No |
| Infection risk | Higher | Lower |
| PEEP maintained | No | Yes |
| Preferred when | Brief disconnect safe | High PEEP, ARDS, COVID-19 |
| Staff PPE | Splash risk | Reduced exposure |
Humidification
Active Humidification (Heated Humidifier)
- Target: 37°C and 44 mg H₂O/L (absolute humidity)
- Uses heated water chamber with heated wire circuit
- Prevents condensation ("rain-out") in tubing
- Preferred for long-term ventilation, thick secretions, HFNO
- Check water chamber level; avoid overfilling; use sterile water
Passive Humidification (HME — Heat & Moisture Exchanger)
- Captures exhaled heat and moisture; returns on next inhalation
- Provides 25–30 mgH₂O/L (less than active humidifier)
- Suitable for short-term ventilation, transport, adequate secretions
- Change every 24 hours; discard if visibly soiled/wet
- Contraindicated: copious/bloody secretions, hypothermia (<32°C), minute volume >10L/min
High Flow Nasal Oxygen (HFNO / Optiflow)
Technical Parameters
- Flow rates: 20–60 L/min (up to 60L/min in adults)
- FiO₂: 21–100% (precisely titrated)
- Gas heated to 37°C and humidified (100% relative humidity)
- Interface: nasal cannula — select correct size (prong occupies ~50% of nostril)
- Washes out nasopharyngeal dead space → reduces CO₂
- Generates low-level CPAP effect (~1cmH₂O per 10L/min)
- Reduces work of breathing; patient comfort superior to standard mask
- Allows eating/drinking/communication
Nursing Monitoring Checklist
- SpO₂ ≥94% (or as targeted for patient)
- Respiratory rate trending down — good sign
- ROX index (SpO₂/FiO₂ / RR) >4.88 at 2h and 12h predicts success (lower = consider escalation)
- Check prong position; nares comfort; moisture in tubing
- If patient deteriorating: escalate to NIV or intubation — avoid delayed escalation
- Document flow, FiO₂, SpO₂, RR hourly
NIV (Non-Invasive Ventilation) — Nursing Monitoring
Indications & Settings
| Condition | Mode | Typical Settings |
|---|---|---|
| COPD exacerbation + hypercapnia | BiPAP | IPAP 14–20 / EPAP 4–6 cmH₂O |
| Cardiogenic pulmonary oedema | CPAP | 5–10 cmH₂O; FiO₂ to ≥94% |
| Obesity hypoventilation | BiPAP | IPAP 16–22 / EPAP 6–10 cmH₂O |
| Post-extubation high risk | BiPAP/CPAP | Individualised |
Nursing Monitoring Checklist
- Interface seal: minimal leak, no noise; skin integrity (nasal bridge — apply dressing prophylactically)
- SpO₂, RR, HR monitored continuously; ABG at 1 hour
- Target ABG at 1h: pH >7.35, improving CO₂; if not → escalate
- Gastric distension: risk if IPAP >20cmH₂O; NGT if needed
- Communication: patient must be able to remove mask in emergency
- Mouth care q4h; keep lips moist
- Absolute contraindications: respiratory arrest, haemodynamic instability, inability to protect airway, facial trauma
Oxygen Delivery Devices — Quick Reference
| Device | Flow Rate | FiO₂ Delivered | GCC Clinical Notes |
|---|---|---|---|
| Nasal cannula | 1–4 L/min | 24–36% | Max 4L for most patients; each 1L/min adds ~4% FiO₂; comfortable for eating/talking |
| Simple face mask | 5–10 L/min | 35–55% | Minimum 5L/min to prevent CO₂ rebreathing; imprecise FiO₂; avoid in COPD |
| Non-rebreather mask | 10–15 L/min | 60–90% | Highest flow available without specialised equipment; use in acute hypoxia, trauma, CO poisoning |
| Venturi mask | 2–15 L/min | 24%, 28%, 35%, 40%, 60% | Precise FiO₂ — use in COPD. Colour-coded valves: blue=24%, white=28%, yellow=35%, red=40%, green=60% |
| HFNO (Optiflow) | 20–60 L/min | 21–100% | Heated/humidified; increasingly available across GCC tertiary centres; ROX index monitoring |
🏃 Pulmonary Rehabilitation
Programme Components & Benefits
Exercise Training
- Aerobic: walking, cycling, treadmill; 20–30 min, 3–5x/week, moderate intensity (Borg 4–6/10)
- Strength/resistance: upper and lower limb; 2–3x/week; improves muscle mass and peripheral oxygen utilisation
- Minimum 8 weeks (ideally 12–24 sessions)
Education Components
- Disease understanding (COPD, asthma, bronchiectasis)
- Inhaler technique & adherence
- Breathlessness management strategies
- Energy conservation techniques
- Exacerbation recognition & early action
- Nutrition and fluid management
Proven Benefits
- Improved exercise tolerance (6MWT improves by 30–50m on average)
- Reduced dyspnoea (MRC scale)
- Improved health-related QoL (CRQ, SGRQ)
- Reduced exacerbations and hospital admissions
- Reduced anxiety and depression
- Improved survival (post-exacerbation PR)
Assessment Tools
6-Minute Walk Test (6MWT)
- 30m flat, unobstructed corridor; patient walks as far as possible in 6 minutes
- Standardised encouragement at 1-minute intervals only
- Record: distance walked, SpO₂ start/end, Borg dyspnoea start/end, HR, reason for stopping
- Normal adult: 400–700m; COPD: 300–450m typical
- Minimum clinically important difference (MCID): 30m improvement
- Contraindicate: unstable angina, recent MI (<1 month), SpO₂ <85% at rest
Peak Flow Zone Calculator
Smoking Cessation
5 A's Framework
- Ask — systematically identify all tobacco users at every contact
- Advise — strongly urge all smokers to quit with clear, personalised messaging
- Assess — determine willingness to quit (Fagerstrom score for dependence; stages of change model)
- Assist — provide counselling, set quit date, prescribe NRT/pharmacotherapy
- Arrange — schedule follow-up within 1 week of quit date; referral to smoking cessation clinic
Pharmacotherapy Options
| Treatment | Dose / Form | Notes |
|---|---|---|
| NRT Patch | 21/14/7mg 24h | Background; combine with acute NRT; safe in stable CVD |
| NRT Gum / Lozenge | 2mg or 4mg | Acute cravings; heavy smokers use 4mg |
| NRT Nasal spray | 0.5mg/actuation | Fastest-acting NRT; most effective for acute cravings |
| NRT Inhaler | 10mg cartridge | Mimics hand-to-mouth habit; suitable for GCC patients |
| Varenicline (Champix) | 0.5mg → 1mg BD | Most effective single agent; monitor mood changes |
| Bupropion | 150mg OD → BD | Contraindicated: seizure history, eating disorders |
COPD Self-Management & Nurse Specialist Role
COPD Action Plan — Traffic Light System
🟢 Green — Feeling Well
Continue all usual medications. Exercise as normal. Follow healthy lifestyle plan.
🟡 Amber — Getting Worse
Increased breathlessness, more sputum, colour change. Start rescue pack (prednisolone 30–40mg × 5 days ± antibiotics). Contact GP within 24 hours.
🔴 Red — Emergency
Severe breathlessness at rest, cyanosis, confusion, cannot complete sentences. Call 999/ambulance immediately. Take all medications with you.
COPD Nurse Specialist — GCC Role
- Initial assessment and spirometry review
- Individualised education and self-management support
- Inhaler review and technique optimisation
- Home visits for high-risk housebound patients
- Exacerbation management in community (avoiding hospital admission)
- Liaison with pulmonologist, physiotherapist, pharmacist, social worker
- Prescribing rescue packs (where prescribing rights granted)
- Coordinating hospital-to-community transitions
- Leading nurse-led COPD / asthma clinics
🌍 GCC Context & Career
Air Quality & Environmental Respiratory Triggers
Sand & Dust Storms
- Khamseen (Egypt/Saudi) — hot, dry southerly wind carrying dense sand; peaks March–May
- Haboob (Gulf/Sudan) — sudden intense dust storm associated with thunderstorm outflow
- PM₁₀ and PM₂.₅ can reach 2,000–10,000 µg/m³ during storms (WHO limit 45 µg/m³)
- Triggers: COPD/asthma exacerbations, acute severe allergic rhinitis, conjunctivitis
- Nursing action: Advise high-risk patients to stay indoors, seal windows, use air filtration, increase inhaler use, ensure rescue packs available
Climate Extremes & Humidity
- High humidity (Gulf coast — Kuwait, Bahrain, UAE coast, Qatar): mould growth risk; house dust mite thrives; worsens allergic asthma
- Dry desert (Riyadh, interior Saudi): low humidity dries airways; increases mucus viscosity; worsens COPD mucus clearance
- Extreme heat (summer 48–52°C): outdoor physical activity severely limited; impacts pulmonary rehabilitation programme scheduling
- Advise patients on indoor air conditioning — allergens, Legionella risk in poorly maintained systems
Smoking Patterns in GCC — Clinical Significance
Shisha / Waterpipe Smoking: Extremely prevalent in GCC Arab population — both male and female. Often falsely perceived as safer than cigarettes (water "filters" toxins — FALSE). One shisha session = 100–200 cigarette equivalents of smoke exposure. Strong risk factor for COPD, lung cancer, oral/oesophageal cancer, cardiovascular disease.
Tobacco Patterns
- Male tobacco smoking prevalence: Saudi 25–32%, UAE 17%, Kuwait 30–35%, Qatar 20%
- Female smoking underreported (social stigma in GCC) — shisha more prevalent
- E-cigarettes/vaping rapidly increasing among youth — long-term consequences unknown; EVALI (e-cigarette/vaping-associated lung injury) cases reported
- Expat workforce (South Asian) — high beedi and bidis use; need culturally sensitive cessation support
Culturally Sensitive Cessation
- Ramadan — natural quit opportunity (no smoking daytime); prepare patient for post-Ramadan relapse prevention
- Smoking cessation is supported in Islamic teaching (harm avoidance / preservation of health — hifz al-nafs)
- Family-based interventions effective — involve spouse, family members in counselling
- Language: ensure Arabic-language educational materials; use trained medical interpreters for non-Arabic speaking staff
Occupational Respiratory Disease in GCC
| Industry / Occupation | Exposure | Respiratory Disease | GCC Prevalence |
|---|---|---|---|
| Construction workers | Crystalline silica (concrete, sandblasting) | Silicosis, COPD, lung cancer | High — millions of construction workers in UAE, Saudi, Qatar |
| Oil & gas workers | Hydrocarbons, H₂S, VOCs, flaring particulates | Occupational asthma, chronic bronchitis, COPD | High — major industry across all GCC |
| Aluminium smelting (Bahrain, UAE) | Aluminium oxide, fluorides | Occupational asthma, aluminosis | Moderate |
| Agriculture/farming | Organic dusts, pesticides | Farmer's lung (EAA), asthma | Lower but increasing (UAE food security push) |
| Healthcare workers | Latex, glutaraldehyde, cleaning agents | Occupational asthma | Significant — monitor symptomatic HCWs |
Nurse action: Always take occupational history in all respiratory patients. Ask specifically about duration of work, respiratory protection use (PPE), work-related symptom variation (improved on holidays/weekends = occupational cause), and compensation rights.
Major Respiratory Centres in GCC
| Hospital / Centre | Country | Specialties |
|---|---|---|
| Rashid Hospital — Chest Medicine Department | Dubai, UAE | Complex COPD, pleural disease, bronchoscopy, ILD, sleep medicine; major trauma/chest injuries |
| Cleveland Clinic Abu Dhabi — Respiratory Institute | Abu Dhabi, UAE | Advanced ILD, lung transplant evaluation, complex asthma, pulmonary hypertension, sleep disorders |
| King Khalid University Hospital — Pulmonology | Riyadh, Saudi Arabia | COPD, asthma, bronchoscopy, sleep medicine, TB management, NIV unit |
| King Faisal Specialist Hospital & Research Centre | Riyadh, Saudi Arabia | Lung transplantation, complex pulmonary hypertension, ILD |
| HMC Pulmonology — Hamad Medical Corporation | Doha, Qatar | COPD, asthma, ILD, respiratory failure, bronchoscopy; MERS-CoV centre |
| Kuwait Chest Disease Hospital | Kuwait City, Kuwait | TB, COPD, asthma, respiratory failure, bronchoscopy, sleep medicine |
| Bahrain Defence Force Hospital | Riffa, Bahrain | COPD, asthma, sleep apnoea; growing pulmonology unit |
Respiratory Nurse Specialist — GCC Career Development
Growing Role in GCC
- COPD nurse-led clinics expanding in Saudi Arabia and UAE following MOH Vision 2030 / chronic disease management programmes
- Asthma nurse specialist roles in tertiary centres (Cleveland Clinic AD, KFSH, HMC)
- Respiratory therapy technologists distinct from nurses in GCC — respiratory nurses bridge clinical care and therapy education
- DHA (Dubai Health Authority) and HAAD (now DOH) recognise specialist respiratory nursing as a scope extension
- Saudi Commission for Health Specialties (SCHS) — Fellowship in Respiratory Nursing under development
Salary Range (2025 Estimates)
| Country | RN Respiratory (SAR/AED/QAR) | Specialist |
|---|---|---|
| Saudi Arabia | SAR 6,500–10,000/month | SAR 12,000–16,000 |
| UAE | AED 7,000–11,000/month | AED 13,000–20,000 |
| Qatar | QAR 7,000–12,000/month | QAR 14,000–22,000 |
| Kuwait | KWD 450–650/month | KWD 700–1,000 |
Tax-free in all GCC countries. Plus accommodation allowance, flights, insurance.